Discovery | Hit Optimization | Lead Optimization | Preclinical Study | IND Filing | Clinical Trials | |
|---|---|---|---|---|---|---|
Gut Target 1 | ||||||
Gut Target 2 |
48HD BioPharma is developing orally delivered, gut restricted peptides to treat colitis, Crohn’s disease, and other inflammatory bowel diseases (IBD). Using 48Hour Discovery’s platform peptide drug discovery technology, 48HD BioPharma has identified several novel bicyclic peptide antagonists for a4b7/MAdCAM that have exceptional proteolytic stability in the gut. Blocking the interaction between a4b7 and MAdCAM has been clinically validated, and shown to reduce inflammation in the gut and decrease the symptoms associated with colitis and other types of IBD. By identifying potent and gut-stable peptides, 48HD BioPharma hopes to develop new classes of oral drugs to improve the lives of patients suffering from IBD.